William Merritt, PhD
Biomedical Engineer · Regenerative Medicine · Standards & Policy
Advancing regenerative medicine through science, standards, and policy.
Biomedical Engineer · Regenerative Medicine · Standards & Policy
Advancing regenerative medicine through science, standards, and policy.
William Merritt, PhD is a biomedical engineer and scientist-entrepreneur building the accountability infrastructure for regenerative medicine in the United States.
Through the American Academy of Stem Cell Medicine (AASCM), Dr. Merritt authored the first comprehensive set of manufacturing standards for stem cell therapies — a 40,000-word, 12-part framework modeled on proven accreditation bodies like AABB (blood banking), FACT (cellular therapy), and CAP (pathology). AASCM conducts on-site facility inspections, awards accreditation, tracks adverse events, and reports clinical outcomes — building the quality layer that the regenerative medicine industry has been missing.
Through the Stem Cell Advocacy Network (SCAN), he advocates for evidence-based state and federal policy that protects patient access to regenerative therapies while demanding scientific accountability from providers.
Dr. Merritt's clinical research includes work in stem cell orthopedic applications, and his broader R&D portfolio spans cell therapy manufacturing, peptide therapeutics, and medical technology — reflected in more than 84 pending patent applications filed across these fields.
He earned his PhD in Biomedical Engineering from Northern Arizona University, where he serves as Affiliate Research Faculty. His doctoral research focused on liquid embolic polymer systems for the treatment of intracranial aneurysms.
He is based in Flagstaff, Arizona.
The regenerative medicine industry operates in a regulatory gap. The FDA's framework for human cells, tissues, and cellular and tissue-based products (HCT/Ps) under 21 CFR Part 1271 establishes important safety guardrails — but it does not prescribe manufacturing standards for facilities processing cell therapy products. The result: wide variation in manufacturing quality, no standardized process controls, and no independent verification that facilities meet any baseline standard of practice. Patients deserve better.
Dr. Merritt authored the AASCM Standards for Stem Cell Manufacturing — a comprehensive, 12-part framework covering:
These standards are process-based, applicable to any cell type, and modeled on the accreditation frameworks of AABB, FACT, and CAP.
The American Academy of Stem Cell Medicine conducts on-site inspections and awards accreditation to facilities that meet these standards — creating a verifiable quality signal for patients, clinicians, payers, and regulators.
Through the Stem Cell Advocacy Network (SCAN), Dr. Merritt advocates for evidence-based legislation that protects patient access to regenerative therapies while demanding scientific accountability from providers.
Additional manuscripts in preparation, including a systematic review of GLP-1 receptor agonist adjunct therapies and an AASCM regulatory gap commentary.
Dr. Merritt's research and development work has produced a broad patent portfolio spanning regenerative medicine, peptide therapeutics, cell therapy manufacturing, and medical technology.
Patent details are proprietary. For inquiries related to licensing or collaboration, please get in touch.
Dr. Merritt is available for speaking engagements, panel discussions, and media commentary on topics including:
For speaking inquiries, please contact Dr. Merritt.
For professional inquiries, research collaboration, speaking requests, or media:
📍 Flagstaff, Arizona
For AASCM-related inquiries, visit the American Academy of Stem Cell Medicine.
For SCAN-related inquiries, visit the Stem Cell Advocacy Network.